Dossier preparation is a critical aspect of regulatory submissions for pharmaceutical products, yet many applicants still make frequent errors that can lead to delays, rejections, or compliance issues. Understanding these common mistakes and learning how to avoid them is essential for anyone involved in the preparation and submission of regulatory dossiers, such as the Common Technical Document (CTD) or Drug Master File (DMF).
Here are the common mistakes:
Supportive clinical and nonclinical full-text articles are often missing from Modules IV and V of the dossier, which are crucial for providing detailed evidence to support the clinical and nonclinical data summaries. Their absence can undermine the dossier's credibility.
There is frequently a lack of proper summarization of literature cited in Modules IV and V within Module II. Additionally, mismatches between the summaries in Module II and the full-text articles in Modules IV and V can create confusion and reduce data reliability.
Photocopies or full references of literature used in Modules IV and V are sometimes illegible, hindering reviewers' ability to verify the information and potentially causing delays or rejections.
Poor binding of the dossier can lead to disorganization and difficulty in handling.
An incomplete table of contents makes it challenging for reviewers to locate specific sections.
The absence of a version number and date hampers the ability to track document revisions.
Faulty pagination disrupts the logical flow and readability of the dossier.
The dossier lacks a complete description of the reactions and steps involved in the API synthesis, which is essential for understanding the manufacturing process. Information on drug substance purification, starting materials, reagents, catalysts, solvents, and intermediates is also incomplete. Furthermore, the mass balance in the reaction scheme is incorrect, raising concerns about the synthetic process's accuracy.
Although toluene is used as a solvent in the synthesis, the dossier fails to test for the presence of residual benzene, a potentially harmful contaminant, raising concerns about the thoroughness of the impurity profile assessment.
Essential physical constants, such as solubility in water, buffers at different pH values, and organic solvents, are not described. These properties are fundamental for understanding the drug substance's behavior, impacting formulation development and stability studies.
The dossier does not address the existence or absence of polymorphism and chirality, which are crucial for ensuring consistent drug performance and bioavailability.
Critical properties like hygroscopicity, particle size distribution, flowability, and granularity are not discussed in detail, affecting the understanding of the API's behavior during manufacturing, storage, and administration.
The API specifications lack attributes beyond those listed in the compendial monograph, such as residual solvents, particle size distribution, chirality, polymorphism, and crystal structure, which are crucial for ensuring the API's quality and consistency.
The Certificate of Analysis (COA) for secondary or working standards is not provided, which is essential for validating the quality and consistency of these standards.
COA and other Quality Control (QC) documents are not signed, dated, or certified by the Quality Assurance (QA) department, compromising the credibility and traceability of these documents.
The dossier relies on literature for forced degradation data instead of providing actual study results, undermining the reliability of the stability assessment.
Stability studies do not utilize stability-indicating methods, which are crucial for detecting changes in the drug's quality over time.
The pharmaceutical development reports are incomplete, lacking comprehensive details about the formulation and development process.
Some excipients used in drug formulations are not included in the batch formula, leading to incomplete formulation details.
The quantity and standard for some excipients are not indicated in the unit and batch formula, and there is a lack of detailed information on commercial colorant mixtures used for tablet coating, including their composition and test methods.
The microbial limit is not included in the finished product (FP) specifications, which is crucial for ensuring the product's microbiological safety.
Some critical documents, such as stability studies reports, method validation, and process validation, are not in English, posing challenges for regulatory reviewers.
No TSE/BSE (Transmissible Spongiform Encephalopathy/Bovine Spongiform Encephalopathy) declaration is provided for sensitive excipients and drugs like Magnesium Stearate, which is essential for safety and compliance.
The dossier lacks a process validation report for the first three commercial batches, which is necessary to demonstrate consistent manufacturing process performance.
Release and stability specifications are not provided, which are crucial for defining the product's quality over its shelf life.
Real-time stability studies have been conducted without considering the appropriate climatic zone conditions, potentially affecting the accuracy of the stability data.
Essential spectral data, such as IR (Infrared Spectroscopy), NMR (Nuclear Magnetic Resonance), Elemental Analysis, and X-Ray Diffraction, are missing, which are vital for confirming the chemical structure and purity of the drug substance.
The dossier does not provide the names and complete contact details of each API manufacturer, and critical details like the route of manufacturing, reaction scheme, brief process, and impurity profiling are missing.
Methods used to assess impurities are not qualified, and potential impurities are not discussed, raising concerns about the thoroughness of the impurity profile.
Inorganic toxic substances and hazardous reagents used in the synthesis are not adequately controlled for residual limits.
Reference standards and materials are not well characterized, compromising the accuracy and reliability of analytical results.
The quality of the APIs meets only specific monograph requirements but fails to meet general monograph specifications, indicating a lack of comprehensive quality assurance.
The specifications for the in-house product are unclear and incomplete, lacking specific tests for identity, impurities, and validated assay methods.
Unknown impurities in the drug substance exceed ICH limits, raising significant concerns about safety and compliance.
Although the drug is known to be polymorphic, this aspect is not discussed, which can impact stability, solubility, and bioavailability.
Residual solvent levels exceed pharmacopoeia limits, posing a safety risk.
There is no justification for the use of excipients that may carry reactive impurities, such as hydrogen peroxide, formaldehyde, and formic acid.
No rationale is provided for using highly hydrated forms of the API, which can affect the drug's stability and efficacy.
The dossier does not include moisture permeation data for the proposed blister pack, which is essential for protecting the drug product from moisture.
An extractable and leachable study for the proposed packaging materials is missing, which is crucial for ensuring no harmful substances leach into the drug product.
ICH Q3C and USP <467> guidelines for controlling solvent residues are not adequately considered, posing a risk to product safety.
Specifications for the container closure system are insufficient; the type of polymer used must be identified and characterized.
Residual metals from the synthetic process are not adequately addressed, necessary for meeting safety standards.
Specifications for intermediates, starting materials, solvents, and reagents are incomplete and misleading.
A specific test for controlling the chirality of the drug substance is not provided, risking the presence of incorrect enantiomers.
The proposed assay procedure is insufficient for controlling chiral impurities.
The source, lot number, and purity of impurity standards are not provided, which are essential for verifying the accuracy of impurity tests.
The analytical report fails to provide results in numerical figures, instead stating "conforms," which lacks specificity.
Quantitative values in the Certificate of Analysis (COA) are below the Limit of Quantitation (LOQ), making them unreliable.
The dossier does not include the Limit of Detection (LOD) and Limit of Quantitation (LOQ) for the HPLC and GC methods.
The same HPLC method is used for both API assay and impurities, but the method is not appropriate for impurity profiling.
Gaps in analytical methods for impurity analysis and API assay, and reliance on nonspecific methods like non-aqueous titration without validation.
The in-house method for analyzing the API and impurities lacks validation, compromising reliability.
Scoring and engraving details for tablet preparations are not provided, which are essential for identification and dosing.
The complete composition of coating materials is not provided; omissions like titanium dioxide cause inconsistencies.
The organic solvent used for film coating is not declared, affecting safety assessments.
Microbial contamination results are missing, raising concerns about microbiological safety.
The stability report lacks packaging details, vital for understanding storage conditions.
Preservatives used in injectable dosage forms are not declared on the label, impacting regulatory compliance and safety.
The expiry date does not match stability data, undermining shelf life reliability.
The specifications for excipients and API do not conform to the latest amendments, indicating non-compliance.
The spectral graphs for IR, NMR, and UV spectra are illegible, compromising identity and purity verification.
Raw materials, intermediates, reagents, and solvents are not controlled for potential impurities, affecting product consistency and safety.
General specifications for drug substances are ignored, leading to incomplete compliance.
Starting materials are not examined for specific chiral or isomeric impurities, which can affect the final product.
No special attention is given to potential differences in quality due to raw materials from different suppliers.
No impurity profiling is conducted for products from different synthesis routes, risking undetected impurities.
Solvents used in synthesis are not analyzed for Class I solvent contamination, which is hazardous.
Residual limits for Class I solvent benzene are not checked, raising safety concerns.
Residual limits for catalysts like palladium and platinum are not specified, essential for safety.
The use of hazardous substances like cyanides poses safety risks; safer alternatives should be considered.
Impurity profiling relies on qualitative TLC tests rather than validated HPLC or GLC methods.
No discussion on carryover impurities from starting materials and intermediates in multi-stage synthesis.
Inadequate prospective and retrospective process validation, emphasizing the need for thorough validation.
In-house analytical procedures lack thorough validation, with vague methods noted by the MOH.
The source of starting materials is not disclosed, crucial for verifying quality and consistency.
No justification for the bio-waiver of products with different strengths.
The stability summary lacks conclusions on storage conditions and shelf-life.
Insufficient data on novel excipients' source, synthesis, characterization, and safety.
Process control details such as moisture, blend uniformity, bulk and tapped densities, and particle size distribution are not provided.
Details like average weight, weight variation, hardness, thickness, friability, and disintegration for tablet dosage form are not provided.
Not all starting materials and excipients are declared, and some hazardous materials are concealed, raising safety concerns.
Residual impurities from hazardous and toxic reagents are not determined, posing safety risks. Also, the in-house analytical method lacks detail, affecting validity and reliability.
Best Regards,
Bhaskar Napte
India’s Leading Pharma Coach
Take this step toward mastering dossier preparation and ensure your submissions are always compliant, accurate, and successful!
Comentários